Intraligamentary Injections and Post-endodontic Pain
Launched by JAMIA MILLIA ISLAMIA · Dec 17, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different injections can help reduce pain after dental treatment for a condition called pulpitis, which is when the innermost part of a tooth becomes inflamed or infected. The study will compare the effects of four different types of injections: dexamethasone, diclofenac sodium, bupivacaine, and lidocaine, all given to patients right after their first dental appointment. The goal is to see which injection provides the best pain relief after the procedure.
To participate in this trial, patients should have specific dental issues, such as having a painful tooth with certain symptoms and a healthy tooth pulp. They should also be in good overall health, without any serious medical conditions or allergies to the medications used in the study. If you join, you can expect to receive one of the injections and share your pain experience afterward, helping researchers understand which option might work best for future patients. Additionally, this trial is open to adults of all genders, aged between 18 and 62.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic carious exposed mandibular first or second molars.
- • Positive and prolonged response to thermal sensitivity tests and electric pulp tests.
- • Vital coronal pulp on access cavity preparation.
- • American Society of Anesthesiologists class I or II medical history.
- • Ability to understand the use of pain scales.
- Exclusion Criteria:
- • Active pain in more than 1 tooth
- • Teeth with fused roots.
- • Radiographic evidence of an extra root.
- • Large restorations with overhanging margins.
- • Full crowns or deep periodontal pockets.
- • Known allergy or contraindications to any content of the local anesthetic solution or NSAIDs
- • History of known or suspected drug abuse.
- • Taking any drugs which could affect the pain perception, e.g, opioids, antidepressants, anticonvulsants, muscle relaxants, anxiolytics, sedatives, NSAIDs.
- • Pregnant or breastfeeding patients.
- • Patients with asthma, gastric ulcers, and bleeding disorders.
About Jamia Millia Islamia
Jamia Millia Islamia (JMI) is a renowned multidisciplinary university located in New Delhi, India, recognized for its commitment to excellence in education, research, and community service. As a clinical trial sponsor, JMI leverages its robust academic framework and diverse research capabilities to advance medical knowledge and improve healthcare outcomes. The institution fosters collaboration among various disciplines, integrating innovative methodologies and ethical practices in clinical research. With a focus on addressing local and global health challenges, JMI aims to contribute to the development of effective therapeutic interventions through rigorous clinical trials and evidence-based research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Delhi, , India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported